

**Anti-CCR2 / CD192 Reference Antibody (plozalizumab)
Recombinant Antibody
Catalog # APR10318**

Specification

Anti-CCR2 / CD192 Reference Antibody (plozalizumab) - Product Information

| | |
|-------------------|-------------------------------|
| Application | FC, E, FTA |
| Primary Accession | P41597 |
| Reactivity | Rat, Cynomolgus, Human, Mouse |
| Clonality | Monoclonal |
| Isotype | IgG1 |
| Calculated MW | 146.08 KDa |

Anti-CCR2 / CD192 Reference Antibody (plozalizumab) - Additional Information

Target/Specificity
CCR2 / CD192

Endotoxin
< 0.001EU/ µg, determined by LAL method.

Conjugation
Unconjugated

Expression system
CHO Cell

Format
Purified monoclonal antibody supplied in PBS, pH6.0, without preservative. This antibody is purified through a protein A column.

Storage
-80°C for 2 years under sterile conditions □ -20°C for 1 year under sterile conditions □ Avoid repeated freeze-thaw cycles.

Anti-CCR2 / CD192 Reference Antibody (plozalizumab) - Protein Information

Name CCR2

Synonyms CMKBR2

Function
Key functional receptor for CCL2 but can also bind CCL7 and CCL12 (PubMed: [23408426](http://www.uniprot.org/citations/23408426), PubMed: [8048929](http://www.uniprot.org/citations/8048929), PubMed: [8146186](http://www.uniprot.org/citations/8146186)). Its binding with CCL2 on monocytes and macrophages mediates chemotaxis and migration induction through the activation of the PI3K cascade, the small G protein Rac and lamellipodium protrusion (Probable).

Also acts as a receptor for the beta-defensin DEFB106A/DEFB106B (PubMed:23938203). Regulates the expression of T-cell inflammatory cytokines and T-cell differentiation, promoting the differentiation of T-cells into T-helper 17 cells (Th17) during inflammation (By similarity). Facilitates the export of mature thymocytes by enhancing directional movement of thymocytes to sphingosine-1-phosphate stimulation and up-regulation of S1P1R expression; signals through the JAK-STAT pathway to regulate FOXO1 activity leading to an increased expression of S1P1R (By similarity). Plays an important role in mediating peripheral nerve injury-induced neuropathic pain (By similarity). Increases NMDA-mediated synaptic transmission in both dopamine D1 and D2 receptor-containing neurons, which may be caused by MAPK/ERK-dependent phosphorylation of GRIN2B/NMDAR2B (By similarity). Mediates the recruitment of macrophages and monocytes to the injury site following brain injury (By similarity).

Cellular Location

Cell membrane; Multi-pass membrane protein. Note=The chemoattractant receptors are distributed throughout the cell surface; after stimulation with a ligand, such as CCL2, they are rapidly recruited into microdomain clusters at the cell membrane.

Tissue Location


Expressed by monocytes and IL2-activated NK cells.

Anti-CCR2 / CD192 Reference Antibody (plozalizumab) - Protocols

Provided below are standard protocols that you may find useful for product applications.


- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

Anti-CCR2 / CD192 Reference Antibody (plozalizumab) - Images



Anti-CCR2 / CD192 Reference Antibody (plozalizumab) on SDS-PAGE under reducing (R) condition.

The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-CCR2 / CD192 Reference Antibody (plozalizumab) is more than 99.45% ,determined by SEC-HPLC.